A Comprehensive Scientific Review

Abstract

Since its emergence in 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been recognized not only as a respiratory pathogen but as a multisystem disease capable of producing substantial injury to the kidneys. Acute kidney injury (AKI) emerged early during the pandemic as one of the strongest predictors of hospitalization, intensive care unit admission, mechanical ventilation, and mortality. Subsequent investigations demonstrated that renal injury may occur through multiple mechanisms, including direct viral invasion, endothelial dysfunction, microvascular thrombosis, dysregulated renin-angiotensin-aldosterone signaling, cytokine-mediated inflammation, complement activation, mitochondrial injury, and immune-mediated pathways. Longitudinal studies have subsequently shown accelerated decline in estimated glomerular filtration rate (eGFR), increased incidence of chronic kidney disease (CKD), and progression to end-stage kidney disease (ESKD) among survivors.

The kidney possesses high expression of angiotensin-converting enzyme 2 (ACE2), the principal receptor utilized by SARS-CoV-2 for cellular entry, rendering renal tubular epithelium particularly susceptible to injury. Emerging genomic investigations further implicate APOL1 risk alleles, inflammatory signaling pathways, mitochondrial dysfunction genes, and host immune polymorphisms as contributors to disease severity.

This review summarizes current understanding of COVID-19–associated kidney disease, detailing epidemiology, molecular biology, pathology, physiology, clinical manifestations, disease progression, therapeutic approaches, methods to preserve renal function, and expected outcomes.

Introduction

The kidneys receive approximately 20% to 25% of cardiac output despite representing less than 1% of body mass. This extraordinary perfusion renders renal tissues highly vulnerable to systemic inflammatory states, microvascular dysfunction, hypoxia, and infectious injury.¹

Although initial attention focused on pulmonary manifestations of Coronavirus Disease 2019 (COVID-19), it rapidly became apparent that renal involvement was both common and clinically significant.²

Among hospitalized patients, AKI rates range from 20% to more than 50%, increasing to over 70% among critically ill individuals requiring mechanical ventilation.³⁻⁵

Evidence accumulated during successive pandemic waves demonstrates that kidney injury may persist long after resolution of acute infection.⁶

Consequently, COVID-19 has become recognized as a major contributor to global CKD burden.

Epidemiology of COVID-19–Associated Kidney Injury

Meta-analyses encompassing millions of patients reveal:

Manifestation	Approximate Incidence
Proteinuria	35–70%
Hematuria	20–50%
Acute Kidney Injury	20–50%
Severe AKI requiring dialysis	5–15%
New CKD after infection	10–30%
Progressive eGFR decline	Up to 35%

AKI increases mortality by 3- to 8-fold.⁷

Mortality exceeds 50% in patients requiring renal replacement therapy.⁸

Patients possessing preexisting CKD represent one of the highest-risk populations during COVID-19 infection.⁹

Etiology of Renal Injury

COVID-associated kidney injury is multifactorial.

1. Direct Viral Cytotoxicity

ACE2 receptors are highly expressed on:

Proximal tubular epithelial cells
Podocytes
Mesangial cells
Renal endothelial cells

Following viral binding, SARS-CoV-2 gains intracellular entry via transmembrane serine protease 2 (TMPRSS2).¹⁰

Subsequent viral replication induces:

Cellular apoptosis
Mitochondrial disruption
Cytoskeletal injury
Tubular necrosis

Autopsy studies have identified viral RNA and viral proteins in renal tissues.¹¹

2. Cytokine-Mediated Injury

Severe COVID-19 may trigger profound inflammatory activation.

Elevated levels include:

IL-1β
IL-6
IL-8
TNF-α
Interferon signaling molecules

These mediators produce:

Endothelial activation
Increased vascular permeability
Tubular injury
Renal hypoperfusion

Collectively termed the “cytokine storm,” this process correlates strongly with AKI severity.¹²

3. Endothelial Dysfunction

Endothelial cells express ACE2 receptors and are frequent targets of infection.

Endothelial injury results in:

Reduced nitric oxide production
Vasoconstriction
Platelet activation
Leukocyte recruitment
Capillary rarefaction

These changes impair glomerular perfusion.¹³

4. Microvascular Thrombosis

COVID-19 induces a profound prothrombotic state.

Observed abnormalities include:

Elevated D-dimer
Fibrin deposition
Platelet aggregation
Complement activation

Renal microthrombi have been observed in numerous autopsy series.¹⁴

Resulting ischemia contributes significantly to nephron loss.

5. Dysregulation of the Renin-Angiotensin System

ACE2 ordinarily converts angiotensin II into angiotensin-(1-7), providing protective anti-inflammatory effects.

SARS-CoV-2 reduces ACE2 availability.

Consequences include:

Excess angiotensin II
Vasoconstriction
Fibrosis
Oxidative stress
Inflammation

The resulting imbalance promotes progressive renal injury.¹⁵

Renal Physiology Relevant to COVID-19

Normal kidney function depends upon:

Glomerular filtration
Tubular reabsorption
Electrolyte regulation
Acid-base balance
Endocrine functions

Each nephron contains:

Glomerulus
Proximal tubule
Loop of Henle
Distal tubule
Collecting duct

Humans possess approximately one million nephrons per kidney.¹⁶

Loss of nephron mass is irreversible.

When nephron injury exceeds compensatory capacity:

eGFR declines
Creatinine rises
Uremia develops

Molecular Mechanisms of Renal Injury

Oxidative Stress

COVID-19 increases reactive oxygen species production.

Reactive oxygen species damage:

DNA
Lipids
Proteins
Mitochondria

Tubular cells are particularly susceptible because of high metabolic demands.¹⁷

Mitochondrial Dysfunction

Renal tubular cells contain dense mitochondrial populations.

SARS-CoV-2 alters:

ATP generation
Electron transport chain activity
Mitophagy pathways

Mitochondrial dysfunction is increasingly recognized as a key mechanism underlying Long COVID renal impairment.¹⁸

Complement Activation

Investigators have identified activation of:

C3
C5b-9
Alternative complement pathways

Excess complement activation promotes endothelial destruction and microvascular injury.¹⁹

Histopathology

Common findings include:

Acute Tubular Injury

Most common lesion.

Features:

Tubular dilation
Brush border loss
Epithelial cell necrosis

Observed in more than 80% of autopsies.²⁰

Collapsing Glomerulopathy

Particularly associated with APOL1 risk alleles.

Features include:

Podocyte collapse
Rapid nephrotic syndrome
Severe proteinuria

Often progresses rapidly to kidney failure.²¹

Thrombotic Microangiopathy

Characterized by:

Endothelial swelling
Fibrin thrombi
Capillary obstruction

Results in ischemic nephron loss.²²

Interstitial Nephritis

Less common but documented.

May arise from:

Immune activation
Drug exposure
Viral-associated inflammation

Genomic Factors

APOL1 Variants

The strongest genetic association involves APOL1 high-risk alleles.

Predominantly observed among individuals of African ancestry.

These variants substantially increase susceptibility to:

Collapsing glomerulopathy
Rapid CKD progression

Following COVID-19 infection, APOL1-associated nephropathy may emerge within days to weeks.²³

HLA Polymorphisms

Genome-wide association studies have implicated:

HLA-DQ
HLA-DR
HLA-B variants

These may influence inflammatory response intensity.²⁴

Interferon Signaling Genes

Variants affecting:

IFNAR2
TYK2
OAS family genes

Appear associated with differential disease severity.²⁵

Mitochondrial Genes

Emerging evidence suggests mitochondrial polymorphisms influence:

Cellular energy production
Oxidative stress responses
Recovery from AKI

Potential implications for Long COVID remain under investigation.²⁶

Progression From AKI to CKD

Historically, AKI was considered reversible.

Modern nephrology recognizes:

AKI → incomplete recovery → fibrosis → CKD

COVID-19 accelerates this sequence through:

Persistent inflammation
Microvascular damage
Fibrogenic signaling
Continued endothelial dysfunction

Survivors demonstrate accelerated annual eGFR decline compared with noninfected controls.²⁷

Part II: Clinical Presentation, Renal Function Loss, eGFR Interpretation, Disease Progression, and Uremia

Clinical Manifestations of COVID-19 Renal Disease

Kidney involvement during acute SARS-CoV-2 infection spans a broad clinical spectrum ranging from asymptomatic urinary abnormalities to fulminant renal failure requiring emergent dialysis.

Many patients exhibit evidence of kidney injury before serum creatinine rises measurably. Consequently, traditional laboratory assessments may underestimate the true prevalence of renal involvement.

Common early manifestations include:

Proteinuria
Albuminuria
Hematuria
Elevated urinary biomarkers
Mild creatinine elevation
Reduced urine concentrating ability

As disease progresses, patients may develop:

Volume overload
Hypertension
Electrolyte abnormalities
Metabolic acidosis
Uremic symptoms
Oliguria
Anuria

Studies from multiple international cohorts demonstrate that proteinuria may precede measurable eGFR decline by weeks or months.²⁸

Early Clinical Signs

The earliest symptoms are often nonspecific.

Patients commonly report:

Fatigue
Reduced exercise tolerance
Metallic taste
Anorexia
Nausea
Cognitive slowing
Increased nocturia
Mild edema

These findings frequently overlap with Long-COVID symptoms.

Consequently, kidney disease may remain unrecognized until substantial nephron loss has occurred.

Laboratory Findings

Serum Creatinine

Creatinine remains the most widely used marker of kidney function.

Normal ranges:

Sex	Normal Creatinine
Male	0.7–1.3 mg/dL
Female	0.6–1.1 mg/dL

Creatinine rises only after significant nephron injury.

Approximately 50% of renal function may be lost before serum creatinine becomes clearly abnormal.²⁹

Blood Urea Nitrogen (BUN)

Normal:

7–20 mg/dL

COVID-associated AKI frequently produces elevations exceeding:

40 mg/dL (moderate injury)
60 mg/dL (severe injury)
100 mg/dL (critical injury)

Elevated BUN strongly predicts mortality.³⁰

Proteinuria

Proteinuria reflects glomerular injury.

Categories:

Protein Excretion	Interpretation
<150 mg/day	Normal
150–500 mg/day	Mild
500–3500 mg/day	Significant
>3500 mg/day	Nephrotic

Proteinuria is among the strongest predictors of future CKD progression following COVID-19.³¹

Albuminuria

Albuminuria frequently appears before eGFR decline.

Microalbuminuria:

30–300 mg/day

Macroalbuminuria:

300 mg/day

Persistent albuminuria indicates ongoing glomerular injury.

Acute Kidney Injury Classification

The internationally accepted KDIGO system defines AKI.

Stage 1

Creatinine:

1.5–1.9 × baseline

Increase ≥0.3 mg/dL

Urine output:

<0.5 mL/kg/hr for 6–12 hr

Stage 2

Creatinine:

2.0–2.9 × baseline

Urine output:

<0.5 mL/kg/hr for >12 hr

Stage 3

Creatinine:

3× baseline

Creatinine ≥4 mg/dL

Dialysis required

Mortality rises dramatically at Stage 3.³²

Estimated Glomerular Filtration Rate (eGFR)

eGFR represents the most clinically useful estimate of kidney function.

Normal adult values:

90–120 mL/min/1.73m²

CKD Staging

Stage	eGFR
G1	≥90
G2	60–89
G3a	45–59
G3b	30–44
G4	15–29
G5	<15

Each decline reflects progressive nephron loss.

Functional Consequences by eGFR

eGFR >90

Function largely preserved.

Potential abnormalities:

Proteinuria
Microscopic hematuria

Most patients remain asymptomatic.

eGFR 60–89

Mild nephron loss.

Possible findings:

Mild hypertension
Microalbuminuria
Increased cardiovascular risk

Symptoms generally absent.

eGFR 45–59

Moderate reduction.

Early manifestations include:

Fatigue
Reduced endurance
Mild anemia

Laboratory abnormalities begin appearing.

eGFR 30–44

Significant nephron loss.

Patients may experience:

Edema
Hypertension
Muscle weakness
Reduced appetite

Anemia becomes common.

Mineral metabolism begins deteriorating.

eGFR 15–29

Severe renal impairment.

Clinical findings:

Persistent fatigue
Nausea
Metallic taste
Weight loss
Cognitive slowing
Pruritus
Restless legs

Secondary hyperparathyroidism develops frequently.

At this stage many nephrologists begin dialysis planning.

eGFR <15

Kidney failure.

Manifestations include:

Uremia
Fluid overload
Hyperkalemia
Acidosis
Severe anemia
Neurologic dysfunction

Dialysis often becomes necessary.

Loss of Renal Function

The relationship between nephron loss and eGFR decline is nonlinear.

Approximate nephron loss:

eGFR	Estimated Nephron Loss
90	Minimal
60	~30%
45	~50%
30	~70%
20	~80%
15	~85–90%
<10	>90%

Remaining nephrons compensate through hyperfiltration.

Unfortunately, hyperfiltration itself accelerates progressive damage.³³

Uremia

Uremia results from accumulation of metabolic toxins normally removed by healthy kidneys.

Important retained toxins include:

Urea
Guanidines
Phenols
Indoles
Middle molecular toxins

These substances exert widespread systemic effects.

Clinical Features of Uremia

Neurologic

Patients may develop:

Brain fog
Memory loss
Cognitive dysfunction
Confusion
Sleep disturbance
Peripheral neuropathy

Advanced cases may progress to:

Seizures
Coma

Gastrointestinal

Common symptoms:

Metallic taste
Anorexia
Nausea
Vomiting
Weight loss

The metallic taste described by many CKD patients often reflects uremic toxin accumulation.

Cardiovascular

Uremia contributes to:

Hypertension
Pericarditis
Arrhythmias
Heart failure

Cardiovascular disease remains the leading cause of death among CKD patients.³⁴

Hematologic

Kidney disease causes reduced erythropoietin production.

Consequences include:

Normocytic anemia
Fatigue
Dyspnea
Reduced exercise tolerance

Hemoglobin often falls below 10 g/dL in advanced disease.

Musculoskeletal

Patients frequently report:

Proximal muscle weakness
Sarcopenia
Muscle cramps
Reduced mobility

The proximal thigh weakness reported by many advanced CKD patients may result from:

Uremic myopathy
Anemia
Electrolyte imbalance
Vitamin D deficiency
Secondary hyperparathyroidism

Long-COVID and Progressive CKD

Studies from the U.S. Department of Veterans Affairs demonstrated that COVID survivors experience accelerated eGFR decline compared with noninfected controls.³⁵

Observed consequences include:

New CKD diagnosis
Accelerated progression
Increased dialysis risk
Increased mortality

Notably, these effects occur even among individuals who never required hospitalization.

Why Some Patients Continue to Lose Kidney Function

Persistent renal injury may result from:

Ongoing inflammation

Residual cytokine activation may persist months after infection.

Microvascular injury

Endothelial dysfunction can continue long after viral clearance.

Fibrosis

Transforming growth factor-beta (TGF-β) drives scar formation.

Mitochondrial dysfunction

Persistent bioenergetic impairment appears increasingly important in Long COVID.

Immune dysregulation

Autoimmune phenomena may contribute to chronic injury.

Risk Factors for Progression

Major predictors include:

Age >65
Diabetes
Hypertension
Obesity
Prior CKD
Proteinuria
Severe AKI during hospitalization
Mechanical ventilation
Elevated inflammatory markers

Predictors of Poor Outcome

The strongest predictors include:

eGFR <30
Heavy proteinuria
Hemoglobin <10 g/dL
Persistent inflammation
Heart failure
Diabetes
Hyperkalemia

Part III: Histopathology, Long-COVID Renal Disease, Therapeutic Interventions, and Strategies to Preserve Renal Function

Histopathology of COVID-19 Kidney Injury

One of the most important discoveries of the pandemic was that SARS-CoV-2 produces multiple distinct patterns of renal injury rather than a single disease process.

Autopsy studies from North America, Europe, China, and South America have consistently demonstrated a spectrum of pathologic findings involving virtually every compartment of the nephron.³⁷

Affected structures include:

Glomeruli
Podocytes
Tubular epithelium
Renal microvasculature
Interstitium
Collecting ducts

The resulting pathology may manifest as acute kidney injury, nephrotic syndrome, chronic kidney disease, or end-stage kidney disease.

Acute Tubular Injury

Acute tubular injury (ATI) remains the most common pathologic finding.

Histologic features include:

Tubular epithelial swelling
Brush border loss
Cytoplasmic vacuolization
Tubular dilation
Cellular necrosis

Microscopically, proximal tubular cells frequently demonstrate severe mitochondrial injury.

Electron microscopy reveals:

Mitochondrial swelling
Cristae disruption
ATP depletion

Because proximal tubular cells require enormous energy expenditure for sodium transport, they are particularly vulnerable to hypoxia and inflammatory injury.

Tubular Cell Apoptosis

Beyond necrosis, SARS-CoV-2 may induce programmed cellular death.

Activated pathways include:

Caspase signaling
Mitochondrial apoptosis pathways
Endoplasmic reticulum stress responses

Tubular apoptosis contributes significantly to nephron loss.

Persistent apoptosis may continue after viral clearance and potentially contributes to Long-COVID kidney dysfunction.³⁸

Endothelial Injury

The renal microvasculature represents one of the primary targets of COVID-19.

Endothelial cells regulate:

Blood flow
Vascular permeability
Coagulation
Inflammatory signaling

SARS-CoV-2–associated endothelial injury produces:

Capillary leak
Microvascular thrombosis
Reduced oxygen delivery
Renal ischemia

The concept of COVID-19 as an endothelial disease has gained substantial support from pathological investigations.³⁹

Microvascular Thrombosis

Autopsy studies frequently demonstrate:

Platelet-rich thrombi
Fibrin deposition
Occluded glomerular capillaries

These lesions reduce oxygen delivery and produce focal nephron infarction.

Many investigators now believe that microvascular injury is among the principal drivers of irreversible nephron loss.

Collapsing Glomerulopathy

One of the most dramatic renal manifestations is COVID-associated collapsing glomerulopathy.

Characteristics include:

Sudden nephrotic syndrome
Massive proteinuria
Rapid decline in eGFR
Severe podocyte injury

Histologically:

Glomerular tuft collapse
Podocyte hypertrophy
Podocyte hyperplasia

The condition resembles HIV-associated nephropathy and frequently progresses rapidly to kidney failure.⁴⁰

Podocyte Injury

Podocytes form the final filtration barrier of the glomerulus.

These highly specialized cells do not regenerate effectively.

COVID-associated podocyte injury results in:

Albuminuria
Proteinuria
Nephrotic syndrome

Loss of podocytes represents one of the most important predictors of progressive CKD.

Interstitial Fibrosis

Regardless of the initiating injury, most chronic kidney diseases ultimately converge upon fibrosis.

Fibrosis involves:

Fibroblast activation
Extracellular matrix deposition
Collagen accumulation
Capillary rarefaction

Once fibrosis becomes established, recovery is limited.

Fibrosis represents the final common pathway leading to irreversible renal failure.

Long-COVID Kidney Disease

Increasing evidence suggests that renal abnormalities may persist for months or years following infection.

Long-COVID kidney disease encompasses:

Persistent proteinuria
Reduced eGFR
Progressive CKD
Ongoing inflammation
Mitochondrial dysfunction

Notably, kidney injury can occur even after relatively mild acute infections.⁴¹

Persistent Inflammation

Several studies demonstrate elevated inflammatory biomarkers months after infection.

Common abnormalities include:

IL-6
TNF-α
CRP
Ferritin

Persistent inflammatory activation promotes:

Fibrosis
Endothelial dysfunction
Progressive nephron loss

Mitochondrial Dysfunction and Long COVID

Healthy renal tubular cells possess among the highest mitochondrial densities in the human body.

Mitochondrial dysfunction can produce:

Reduced ATP generation
Oxidative stress
Cellular senescence
Fibrogenesis

Researchers increasingly suspect mitochondrial dysfunction contributes substantially to prolonged renal impairment following COVID infection.⁴²

Autoimmunity

COVID-19 may trigger autoantibody production.

Reported antibodies include:

Antinuclear antibodies
Antiphospholipid antibodies
Anti-endothelial antibodies

These immune abnormalities may contribute to persistent renal injury.

Therapeutic Approaches

Management depends upon disease stage and severity.

Goals include:

Preserve remaining nephron function.
Reduce proteinuria.
Control blood pressure.
Prevent fibrosis.
Delay dialysis.
Reduce cardiovascular mortality.

Blood Pressure Control

Hypertension accelerates nephron loss.

Target blood pressure:

Generally <130/80 mmHg.

Adequate control significantly slows CKD progression.⁴³

ACE Inhibitors

Common agents include:

Lisinopril
Enalapril
Ramipril

Benefits include:

Reduced intraglomerular pressure
Reduced proteinuria
Slowed fibrosis
Preservation of eGFR

Proteinuria reduction often predicts long-term renal preservation.

Angiotensin Receptor Blockers (ARBs)

Examples include:

Losartan
Valsartan
Irbesartan

ARBs produce effects similar to ACE inhibitors and are often used when cough or intolerance occurs.

SGLT2 Inhibitors

A major advance in nephrology has been the emergence of SGLT2 inhibitors.

Examples:

Empagliflozin
Dapagliflozin
Canagliflozin

Benefits include:

Reduced hyperfiltration
Reduced proteinuria
Slower eGFR decline
Reduced dialysis risk

Trials demonstrate approximately 30–40% reductions in progression to kidney failure.⁴⁴

Mineralocorticoid Receptor Antagonists

The nonsteroidal agent:

Finerenone

has demonstrated significant renal benefits.

Mechanisms include:

Reduced fibrosis
Reduced inflammation
Reduced albuminuria

Particularly beneficial in diabetic kidney disease.

Hyperkalemia monitoring remains essential.

GLP-1 Receptor Agonists

Agents include:

Semaglutide
Tirzepatide

Benefits include:

Improved glycemic control
Weight reduction
Reduced inflammation
Cardiovascular protection

Emerging evidence suggests direct renal protective effects.

Protein Restriction

Moderate protein restriction may reduce:

Hyperfiltration
Nitrogenous waste generation
Uremic symptoms

Typical recommendations:

0.6–0.8 g/kg/day

for advanced CKD patients under physician supervision.

Sodium Restriction

Excess sodium promotes:

Hypertension
Proteinuria
Volume overload

Target intake:

<2 grams sodium daily

for many CKD patients.

Anemia Management

Declining renal function reduces erythropoietin production.

Treatment may involve:

Iron replacement
Erythropoiesis-stimulating agents
Blood transfusions in selected cases

Correcting anemia improves exercise capacity and quality of life.

Metabolic Acidosis

Acidosis accelerates CKD progression.

Treatment often includes:

Oral bicarbonate therapy
Dietary modification

Correction slows nephron loss in many patients.⁴⁵

Hyperkalemia Prevention

As kidney function declines, potassium excretion diminishes.

High potassium may produce:

Muscle weakness
Arrhythmias
Sudden death

Management includes:

Dietary restriction
Diuretics
Potassium-binding agents

Can Renal Function Be Salvaged?

The answer depends on the degree of fibrosis already present.

Potentially Reversible Components

Inflammation
Hemodynamic injury
Hyperfiltration
Volume overload
Drug toxicity
Obstruction

Largely Irreversible Components

Extensive fibrosis
Global glomerulosclerosis
Severe nephron loss

The earlier intervention occurs, the greater the probability of preserving function.

Renal Recovery After COVID

Recovery categories include:

Complete Recovery

Return to baseline eGFR.

Partial Recovery

Improved function but persistent CKD.

Progressive Disease

Ongoing eGFR decline.

End-Stage Kidney Disease

Permanent dialysis dependence.

Patients who recover from AKI but retain eGFR below 60 remain at elevated risk for progressive CKD years later.⁴⁶

Part IV: End-Stage Kidney Disease, Dialysis, Renal Transplantation, Prognosis, Mortality, and Comprehensive Renal Salvage Strategies

Progression to End-Stage Kidney Disease (ESKD)

The ultimate consequence of severe COVID-19–associated kidney injury is progression to End-Stage Kidney Disease (ESKD), defined as irreversible loss of renal function requiring renal replacement therapy or transplantation.

ESKD occurs when remaining nephron mass can no longer sustain:

Fluid balance
Electrolyte homeostasis
Acid-base regulation
Toxin elimination
Endocrine functions

Although not all patients with COVID-associated AKI develop ESKD, multiple longitudinal studies have demonstrated accelerated progression among survivors compared with noninfected populations.⁴⁷

The Nephron Loss Threshold

The kidneys possess remarkable reserve capacity.

Clinical symptoms often remain minimal until approximately 70–80% of nephron function has been lost.

Compensatory mechanisms include:

Hyperfiltration
Increased single-nephron GFR
Tubular hypertrophy
Hormonal adaptation

Unfortunately, these same mechanisms eventually accelerate progressive injury.

This phenomenon is termed maladaptive hyperfiltration.⁴⁸

Clinical Manifestations of ESKD

When eGFR approaches 10–15 mL/min/1.73m², symptoms typically become increasingly prominent.

Common manifestations include:

Constitutional

Severe fatigue
Weight loss
Frailty
Reduced exercise capacity

Neurologic

Cognitive dysfunction
Memory impairment
Sleep disturbances
Peripheral neuropathy
Restless leg syndrome

Gastrointestinal

Metallic taste
Persistent nausea
Vomiting
Loss of appetite

Dermatologic

Pruritus
Dry skin
Easy bruising

Cardiovascular

Hypertension
Congestive heart failure
Arrhythmias

Uremic Syndrome

Uremia represents systemic toxicity resulting from retention of substances normally excreted by healthy kidneys.

More than 150 known uremic toxins have been identified.⁴⁹

Major toxin groups include:

Small Solutes

Urea
Creatinine

Middle Molecules

β2-microglobulin
Cytokines

Protein-Bound Toxins

Indoxyl sulfate
p-Cresyl sulfate

These compounds contribute to:

Endothelial dysfunction
Cardiovascular disease
Cognitive impairment
Immune dysfunction

Uremic Encephalopathy

Progressive toxin accumulation affects the central nervous system.

Symptoms include:

Brain fog
Slowed cognition
Memory impairment
Personality changes
Somnolence

Advanced disease may progress to:

Seizures
Coma
Death

This complication represents an absolute indication for dialysis.

Uremic Myopathy

Many advanced CKD patients experience profound proximal muscle weakness.

Clinical findings include:

Difficulty rising from chairs
Difficulty climbing stairs
Reduced grip strength
Sarcopenia

Mechanisms include:

Mitochondrial dysfunction
Inflammation
Acidosis
Anemia
Neuropathy

The proximal thigh weakness frequently reported in advanced kidney disease often reflects multiple overlapping mechanisms.

Hyperkalemia

Potassium balance becomes increasingly impaired as eGFR declines.

Normal potassium:

3.5–5.0 mmol/L

Clinical risk increases when potassium exceeds:

5.5 mmol/L: mild
6.0 mmol/L: significant
6.5 mmol/L: emergency

Severe hyperkalemia may cause:

Ventricular arrhythmias
Cardiac arrest
Sudden death

Metabolic Acidosis

Healthy kidneys regenerate bicarbonate and excrete hydrogen ions.

Loss of nephron mass produces:

Reduced bicarbonate
Progressive acidosis

Consequences include:

Bone loss
Muscle wasting
Increased inflammation
Accelerated CKD progression

Dialysis

Dialysis replaces a portion of kidney function but does not restore native renal physiology.

Primary goals:

Remove toxins
Remove excess fluid
Correct electrolyte abnormalities
Correct acidosis

Indications for Dialysis

Classic indications include:

A – Acidosis

Severe refractory metabolic acidosis

E – Electrolytes

Life-threatening hyperkalemia

I – Intoxications

Selected poisonings

O – Overload

Fluid overload unresponsive to therapy

U – Uremia

Pericarditis, encephalopathy, severe symptoms

Hemodialysis

Hemodialysis remains the most common modality.

Typical schedule:

Three sessions weekly
3–5 hours per treatment

Advantages:

Efficient clearance
Broad availability

Disadvantages:

Vascular access complications
Hypotension
Transportation burden

Peritoneal Dialysis

Peritoneal dialysis utilizes the peritoneal membrane as a natural filter.

Advantages:

Home-based therapy
Greater independence
Better hemodynamic stability

Disadvantages:

Peritonitis risk
Catheter complications

COVID-19 and Dialysis Patients

Dialysis patients represent one of the highest-risk populations.

Contributing factors include:

Immune dysfunction
Cardiovascular disease
Frequent healthcare exposure

Mortality during acute infection was substantially elevated compared with the general population.⁵⁰

Renal Transplantation

Kidney transplantation remains the preferred treatment for suitable ESKD patients.

Benefits include:

Improved survival
Improved quality of life
Greater physiologic function
Reduced cardiovascular mortality

However, immunosuppression introduces additional infection risks.

COVID-19 in Kidney Transplant Recipients

Transplant recipients experience:

Increased hospitalization
Increased mortality
Higher viral burden
Prolonged viral shedding

Management requires careful balancing of:

Rejection prevention
Infection control

Expected Outcomes by eGFR

eGFR >60

Most individuals remain asymptomatic.

Annual decline:

Approximately 0.5–1 mL/min/year with healthy aging.

eGFR 45–59

Risk increases for:

Cardiovascular disease
Hypertension
Progressive CKD

Many patients remain stable for years.

eGFR 30–44

Substantial increase in:

Hospitalization
Anemia
Mortality

Progression risk accelerates.

eGFR 15–29

High likelihood of:

Symptomatic CKD
Metabolic complications
Dialysis planning

Five-year risk of kidney failure rises significantly depending on albuminuria burden.⁵¹

eGFR <15

Kidney failure.

Without dialysis or transplantation:

Progressive uremia
Fluid overload
Hyperkalemia
Death

Mortality and CKD

Mortality increases progressively with declining eGFR.

Approximate relative mortality risk:

eGFR	Relative Mortality Risk
>90	Baseline
60–89	Slightly elevated
45–59	1.2–1.5×
30–44	2–3×
15–29	4–6×
<15	>10×

Cardiovascular disease accounts for the majority of deaths.⁵²

Comprehensive Renal Salvage Strategy

Current evidence suggests maximal preservation of kidney function requires simultaneous attention to multiple pathways.

1. Blood Pressure Control

Target generally:

<130/80 mmHg

Avoid excessive hypotension that may compromise renal perfusion.

2. Glycemic Control

Target HbA1c often:

Approximately 7%

Individualized according to age and comorbidity.

Poor glycemic control accelerates nephron loss.

3. Proteinuria Reduction

Proteinuria itself damages remaining nephrons.

Primary interventions:

ACE inhibitors
ARBs
SGLT2 inhibitors
Finerenone

4. Avoid Nephrotoxins

Important nephrotoxins include:

NSAIDs
Radiographic contrast
Aminoglycosides
Certain chemotherapeutics

Avoidance can prevent substantial additional injury.

5. Volume Optimization

Both dehydration and fluid overload can worsen renal injury.

Maintenance of euvolemia is essential.

6. Treat Metabolic Acidosis

Maintaining bicarbonate above approximately 22 mmol/L slows CKD progression.

7. Correct Anemia

Targeted correction improves:

Exercise tolerance
Cardiac function
Quality of life

8. Nutritional Optimization

Goals include:

Adequate calories
Controlled sodium
Appropriate protein intake
Potassium management

9. Cardiovascular Risk Reduction

The leading cause of death in CKD remains cardiovascular disease rather than kidney failure itself.

Interventions include:

Statins
Blood pressure control
Diabetes management
Smoking cessation

Can Lost Kidney Function Be Recovered?

Recovery depends upon the nature of the injury.

Potentially Recoverable

Acute tubular injury
Inflammation
Hemodynamic dysfunction
Drug-induced injury

Partially Recoverable

Moderate fibrosis
Segmental glomerular injury

Generally Irreversible

Extensive nephron destruction
Global glomerulosclerosis
Advanced fibrosis

Once a nephron is completely lost, regeneration is extremely limited.

Thus, preservation of surviving nephrons remains the central objective of modern nephrology.

Part V: Future Therapeutic Directions, Emerging Research, Regenerative Medicine, Clinical Trials, Conclusions, and Complete Reference Expansion

Future Directions in COVID-19 Kidney Research

Six years after the emergence of SARS-CoV-2, substantial questions remain regarding the mechanisms responsible for persistent renal dysfunction. Although acute kidney injury is now well characterized, Long-COVID kidney disease remains incompletely understood.

Major unanswered questions include:

Why some individuals recover fully while others develop progressive CKD.
The extent to which persistent viral reservoirs contribute to ongoing injury.
The role of mitochondrial dysfunction.
The significance of autoimmunity and immune dysregulation.
Whether renal fibrosis can be reversed.
Which therapies most effectively preserve remaining nephron function.

Large international studies continue to investigate these questions.

Long-COVID and Persistent Renal Injury

Accumulating evidence suggests that COVID-19 may accelerate biological aging processes within the kidney.

Potential mechanisms include:

Cellular Senescence

Injured cells may enter a state of permanent metabolic dysfunction.

Characteristics include:

Chronic inflammation
Cytokine production
Fibrogenic signaling
Impaired regeneration

Senescent cells may persist long after viral clearance.⁵³

Persistent Endothelial Dysfunction

Endothelial abnormalities have been documented months after infection.

Findings include:

Reduced nitric oxide production
Impaired vasodilation
Microvascular dysfunction
Increased thrombotic tendency

Because healthy kidney function depends heavily on microvascular integrity, prolonged endothelial injury may contribute substantially to progressive eGFR decline.

Persistent Immune Activation

Studies demonstrate ongoing elevations in:

IL-6
TNF-α
Interferon-related pathways

This persistent inflammatory environment may drive chronic fibrosis and nephron loss.

Biomarkers Under Investigation

Researchers are actively evaluating novel biomarkers capable of detecting injury before substantial nephron loss occurs.

Promising candidates include:

NGAL

Neutrophil gelatinase-associated lipocalin

Appears rapidly after tubular injury.

KIM-1

Kidney injury molecule-1

Sensitive marker of proximal tubular damage.

Cystatin C

May detect reduced filtration earlier than creatinine.

TIMP-2 and IGFBP7

Markers of cellular stress.

These biomarkers may eventually allow earlier intervention than traditional creatinine-based monitoring.⁵⁴

Artificial Intelligence and Kidney Disease Prediction

Machine-learning algorithms increasingly assist clinicians in predicting:

AKI development
CKD progression
Dialysis requirement
Mortality risk

Future systems may integrate:

Laboratory values
Genomics
Imaging
Biomarker profiles

to provide individualized risk assessments.

Regenerative Medicine

One of the most exciting areas of nephrology involves regenerative therapies.

Historically, nephron loss has been considered irreversible.

Modern research seeks to challenge this paradigm.

Stem Cell Therapy

Mesenchymal stem cells possess:

Anti-inflammatory properties
Immunomodulatory effects
Tissue-repair capabilities

Animal studies demonstrate:

Reduced fibrosis
Improved renal perfusion
Enhanced recovery after AKI

Human trials remain ongoing.⁵⁵

Extracellular Vesicles and Exosomes

Stem cells may exert many of their beneficial effects through exosomes.

Exosomes contain:

RNA
MicroRNA
Proteins
Growth factors

Experimental studies suggest exosome therapies may reduce inflammation and fibrosis.

Gene-Based Therapeutics

Future therapies may target:

APOL1

Reducing risk associated with collapsing glomerulopathy.

Fibrosis Pathways

Targeting:

TGF-β
Connective tissue growth factor
Fibroblast activation pathways

Mitochondrial Function

Improving cellular bioenergetics.

Several investigational agents are currently in early-stage development.

Antifibrotic Therapies

Fibrosis remains the principal determinant of irreversible kidney failure.

Investigational antifibrotic approaches include:

TGF-β inhibition
Integrin modulation
Connective tissue growth factor inhibition
Galectin-3 inhibition

If successful, these therapies could fundamentally alter CKD management.

Complement Inhibition

Excess complement activation contributes to:

Endothelial injury
Microvascular thrombosis
Inflammation

Agents targeting:

C3
C5
Alternative pathway activation

remain under investigation.

Early results appear promising in selected populations.⁵⁶

Mitochondrial Therapeutics

Mitochondrial dysfunction has emerged as a recurring theme in Long COVID.

Potential interventions include:

Coenzyme Q10
Mitochondria-targeted antioxidants
NAD+ augmentation strategies
Mitophagy-enhancing therapies

Although evidence remains preliminary, this area has generated substantial interest.

The Implantable Artificial Kidney

One of the most transformative technologies under development is the implantable bioartificial kidney.

Goals include:

Continuous filtration
Reduced dependence on dialysis
Improved quality of life

Several research programs have demonstrated encouraging progress.

Although widespread availability remains years away, the concept represents a potentially revolutionary advance.⁵⁷

Xenotransplantation

Genetically modified porcine organs have recently demonstrated feasibility in experimental transplantation.

Potential advantages include:

Expanded organ supply
Reduced waiting times
Increased transplantation access

Substantial scientific and ethical challenges remain.

Major Ongoing Clinical Research

Important international initiatives include:

RECOVER Initiative

Sponsored by the National Institutes of Health

Investigates:

Long COVID
Organ-specific injury
Therapeutic interventions

Kidney Precision Medicine Project

Examines molecular pathways underlying CKD progression.

APOL1 Research Programs

Focused on genetic susceptibility and targeted therapies.

SGLT2 Extension Studies

Evaluating long-term renal protection.

Finerenone Outcome Trials

Assessing effects on fibrosis and CKD progression.

Prognosis

Outcomes vary substantially depending upon:

Baseline kidney function
Degree of AKI
Proteinuria burden
Age
Diabetes status
Cardiovascular disease
Recovery of renal function

Patients who avoid severe fibrosis often experience stabilization.

Patients with persistent proteinuria remain at elevated risk for progression.

Key Clinical Principles

Several principles emerge consistently from contemporary research:

Principle 1

COVID-19 is a multisystem vascular disease capable of directly and indirectly damaging the kidneys.

Principle 2

Proteinuria frequently precedes measurable eGFR decline.

Principle 3

Acute kidney injury substantially increases long-term CKD risk.

Principle 4

Persistent inflammation and endothelial dysfunction may continue after apparent recovery.

Principle 5

Early intervention provides the greatest opportunity for preserving nephron function.

Principle 6

SGLT2 inhibitors, RAAS blockade, blood-pressure control, and metabolic optimization currently represent the most effective evidence-based strategies for slowing progression.

Principle 7

Once extensive fibrosis develops, recovery becomes increasingly limited.

Conclusions

COVID-19–associated kidney injury represents one of the most important nonpulmonary complications of SARS-CoV-2 infection. Evidence accumulated over the past several years demonstrates that renal injury occurs through a complex interplay of direct viral cytotoxicity, endothelial dysfunction, microvascular thrombosis, complement activation, immune dysregulation, mitochondrial injury, and maladaptive repair mechanisms.

The clinical spectrum ranges from asymptomatic proteinuria to fulminant acute kidney injury and end-stage kidney disease. Longitudinal studies reveal accelerated decline in kidney function among survivors, including individuals who experienced relatively mild acute infections. Persistent proteinuria, chronic inflammation, endothelial dysfunction, and fibrosis appear central to long-term disease progression.

Current therapeutic strategies emphasize preservation of remaining nephron mass through meticulous blood pressure control, proteinuria reduction, optimization of metabolic parameters, avoidance of nephrotoxins, and use of renoprotective pharmacologic agents such as ACE inhibitors, ARBs, SGLT2 inhibitors, and finerenone where appropriate. Emerging therapies targeting fibrosis, complement activation, mitochondrial dysfunction, and regenerative pathways offer hope for future advances.

As the global population of COVID-19 survivors continues to age, recognition and management of post-COVID kidney disease will remain a major priority for nephrologists, internists, and public health systems worldwide.

References

Brenner BM, Rector FC. The Kidney. 11th ed.
Hirsch JS et al. Kidney Int. 2020.
Cheng Y et al. Kidney Int. 2020.
Chan L et al. JASN. 2021.
Gupta RK et al. Nat Rev Nephrol. 2021.
Al-Aly Z et al. Nat Med. 2021.
Ng JH et al. Kidney Int. 2021.
Flythe JE et al. JASN. 2021.
Henry BM, Lippi G. Clin Chim Acta. 2020.
Hoffmann M et al. Cell. 2020.
Puelles VG et al. NEJM. 2020.
Mehta P et al. Lancet. 2020.
Varga Z et al. Lancet. 2020.
Ackermann M et al. NEJM. 2020.
South AM et al. Hypertension. 2020.
Guyton AC, Hall JE. Textbook of Medical Physiology.
Su H et al. Kidney Int. 2020.
Singh KK et al. Front Immunol. 2022.
Java A et al. Kidney Int. 2020.
Golmai P et al. Kidney Int Rep. 2020.
Larsen CP et al. Kidney Int Rep. 2020.
Jhaveri KD et al. Kidney Int. 2020.
Kudose S et al. Kidney Int Rep. 2020.
Severe Covid GWAS Group. Nature. 2020.
Pairo-Castineira E et al. Nature. 2021.
Saleh J et al. Front Med. 2022.
Bowe B, Xie Y, Al-Aly Z. JASN. 2022.
Fakhouri F, et al. Nat Rev Nephrol. 2022.
Stevens PE, Levin A. Kidney Int Suppl. 2013.
Cheng Y, et al. Kidney Int. 2020.
Nadim MK, et al. Nat Rev Nephrol. 2020.
KDIGO Clinical Practice Guidelines for AKI. Kidney Int Suppl. 2012.
Brenner BM. Am J Kidney Dis. 1985. Go AS et al.
NEJM. 2004. Al-Aly Z, Bowe B, Xie Y. Nat Med. 2022.
Matsushita K et al. Lancet. 2010.
Sharma P et al. Kidney Int. 2020.
Werion A et al. JASN. 2020.
Varga Z et al. Lancet. 2020. May RM et al. Kidney Int Rep. 2021.
Bowe B et al. JASN. 2022.
Singh KK et al. Front Immunol. 2022.
KDIGO Blood Pressure Guideline. Kidney Int. 2021.
Heerspink HJL et al. NEJM. 2020. de Brito-Ashurst I et al.
JASN. 2009. Hsu RK, Hsu CY. Nat Rev Nephrol. 2016.
Nugent J et al. CJASN. 2021.
Brenner BM. Kidney Int. 1983.
Vanholder R et al. Kidney Int. 2003.
Hsu CM et al. JASN. 2021.
Tangri N et al. JAMA. 2011.
Go AS et al. NEJM. 2004
Kirkland JL, Tchkonia T. EBioMedicine. 2020.
Kashani K, et al. Crit Care. 2013.
Humphreys BD, Bonventre JV. Annu Rev Pathol. 2008.
Java A, Apicelli AJ, Liszewski MK, et al. Kidney Int. 2020.
Fissell WH, Roy S. Kidney Int. 2009.
Al-Aly Z, Xie Y, Bowe B. Nat Med. 2022.
Jager KJ, et al. Nat Rev Nephrol. 2021.
Kellum JA, Romagnani P, Ashuntantang G, et al. Nat Rev Dis Primers. 2021.
Ronco C, Reis T, Husain-Syed F. Lancet Respir Med. 2020.
Batlle D, Soler MJ, Sparks MA, et al. JASN. 2020.
Peired AJ, Antonelli G, Angelotti ML, et al. Nat Rev Nephrol. 2021.
Levey AS, Coresh J. Lancet. 2012.
Levin A, Stevens PE. Kidney Int Suppl. 2014.
Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. NEJM. 2020.
Bakris GL, Agarwal R, Anker SD, et al. NEJM. 2020.
Perkovic V, Jardine MJ, Neal B, et al. NEJM. 2019.
Bowe B, Cai M, Xie Y, et al. JASN. 2021.
Rewa O, Bagshaw SM. Nat Rev Nephrol. 2014.